Risk factor
Good trading liquidity
Profitability factor
Very low or no dividends
About
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, overpric
Target Price
The average target price of ARGX is 1070 and suggests 51% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell